Skip to main content
Clinical Trials/NCT04488913
NCT04488913
Completed
Not Applicable

Rapid Acute Coronary Syndrome Exclusion Using the Beckman Coulter Access High-sensitivity I Troponin

Henry Ford Health System1 site in 1 country32,609 target enrollmentJuly 29, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Chest Pain
Sponsor
Henry Ford Health System
Enrollment
32609
Locations
1
Primary Endpoint
Safe ED discharge
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

As part of the planned implementation of a new clinical pathway using hs-cTnI, the investigators will measure patient outcomes and clinical processes in a real-world scenario throughout an integrated health system across 9 emergency departments (ED).

Detailed Description

This is a pragmatic, implementation study testing the implications of a real-world execution of a rapid evaluation pathway for suspected ACS using the Beckman hs-cTnI assay. As the new protocol is executed across 9 EDs within an integrated health system, the investigators will study its effects on patient and system-level metrics. A modified stepped wedge design will be utilized that allows comparison of the RACE-IT pathway with standard of care management

Registry
clinicaltrials.gov
Start Date
July 29, 2020
End Date
March 3, 2022
Last Updated
4 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Joseph Miller, MD

Principal Investigator

Henry Ford Health System

Eligibility Criteria

Inclusion Criteria

  • Patients ≥18 years old presenting to the ED for whom a treating clinician suspects ACS and orders a baseline ECG and cardiac troponin.

Exclusion Criteria

  • ST-segment Myocardial Infarction (STEMI) leading to immediate reperfusion therapy
  • Any ED-drawn hs-cTnI value \> 99th percentile (18 ng/L)
  • Clear traumatic cause for symptoms (e.g., direct chest wall trauma, motor vehicle accident)
  • A transfer from another facility
  • Primary residence outside the state of Michigan
  • Previous inclusion in the study
  • Enrolled in hospice

Outcomes

Primary Outcomes

Safe ED discharge

Time Frame: 30 days after initial presentation

Proportion of patients with safe discharges home from the ED, defined as being without death or acute myocardial infarction within 30-days

Secondary Outcomes

  • Number of participants with revascularization or rehospitalization for cardiovascular disease(30-days)
  • Number of participants with death or acute myocardial infarction(30-day and through 1 year)
  • Length of hospital stay(From date and time of start of emergency department encounter until date and time of end of ED or hospital encounter (whichever is latest), assessed up to 7 days.)
  • Composite number of cardiology resources utilized(30-days)
  • Hospital payments received(30-days)

Study Sites (1)

Loading locations...

Similar Trials